- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01205386
Crosser Enters The Right Arterial Lumen (CENTRAL)
September 6, 2013 updated by: C. R. Bard
The purpose of this study is to determine if the CROSSER CTO Recanalization System can facilitate the successful crossing of Chronic Total Occlusions in the Central lumen of the Superficial Femoral Artery (SFA).
A Chronic Total Occlusion (CTO) is defined as 100% narrowing of the artery, with no angiographically detectable antegrade blood flow, and the assessment that the lesion has been in existence for a minimum of 30 days.
This study will enroll up to 100 patients at up to 8 clinical sites.
The CROSSER CTO Recanalization System was cleared for commercialization by the US Food & Drug Administration.
This study also involves an imaging device called the IVUS (Intravascular Ultrasound Imaging) catheter.
This device has been cleared for commercialization by the US Food and Drug Administration and will be studied for its cleared intended use.
The IVUS catheter is used to generate real-time images of the artery, which will allow for evaluation of the artery after the occlusion is crossed.
This is a post-market registry.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center
-
-
Iowa
-
Des Moines, Iowa, United States, 50325
- Iowa Methodist Medical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48236
- St. John Hospital and Medical Center
-
Wyoming, Michigan, United States, 49519
- Metro Health Hospital
-
-
Minnesota
-
Coon Rapids, Minnesota, United States, 55433
- Mercy Heart and Vascular Center
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45243
- The Christ Hospital
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- Memphis Heart Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with CTO who are indicated for recanalization.
Description
Inclusion Criteria:
- Patient must have objective evidence of lower extremity ischemia and scheduled to undergo an endovascular recanalization.
- Occluded artery must be the native superficial femoral artery.
- Patient must have a totally occlusive lesion classified angiographically as absolute (100% occlusion with no flow).
- Patient's target vessel occlusion length is ≤ 30 cm.
- Patient's reference vessel diameter is greater than or equal to 3.0mm.
- Patient must be an acceptable candidate for PTA, peripheral artery bypass surgery or peripheral artery stent implantation.
- Female patients of child bearing potential must have a negative pregnancy test within 72 hours prior to the study procedure.
- Patient or guardian must have been informed of the nature of the study, agree to its provisions, and provide written informed consent.
- Patient is ≥ 18 years of age.
Exclusion Criteria:
- Patient has hypersensitivity or contraindication to aspirin, heparin or radiographic contrast agents which cannot be adequately pre-medicated.
- The patient requires immediate treatment in more than one occluded vessel, in any combination of grafts or native vessels.
- Patient's occlusion is a flush occlusion initiating less than 2cm from the ostium.
- Patient has planned infrainguinal intervention scheduled within 30 days after index procedure.
- The patient is currently participating in another investigational drug or device trial that may conflict with study data collection and has not completed the entire follow-up period.
- Patient has no collateral flow distal to the occlusion.
- Patient's target occlusion has a dissection that occurred within the past 60 days caused by a guidewire attempt.
- Patient has a history of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency.
- Patient suffered recent (within the past 6 months) stroke or transient ischemic neurological attack (TIA).
- Patient suffered recent (within the past 6 months) significant gastrointestinal (GI) bleeding.
- Patient has other medical illnesses (i.e., cancer or congestive heart failure) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with life-expectancy less than 1 year.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CROSSER
|
The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery).
The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Crosser navigates through the central lumen of the artery
Time Frame: At time of procedure (day 0)
|
Successful navigation of the CROSSER CTO Recanalization Catheter in the central lumen of the artery as confirmed by Intravascular Ultrasound (IVUS) following recanalization
|
At time of procedure (day 0)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success - crossing the CTO into the true distal lumen
Time Frame: At time of procedure (Day 0)
|
The ability to facilitate crossing the CTO into the true distal lumen with the CROSSER Catheter and/or any conventional guidewire after use of the CROSSER.
|
At time of procedure (Day 0)
|
Procedural Success - Technical success plus residual stenosis < 50% and improved flow
Time Frame: Time of Procedure (Day 0)
|
Achievement of Technical Success plus a residual stenosis <50%, and improved flow verified angiographically, at the conclusion of the procedure.
|
Time of Procedure (Day 0)
|
Clinical Success - freedom from limb loss and repeat revascularization
Time Frame: 6 month follow-up
|
Clinical Success - freedom from limb loss, and repeat revascularization (bypass surgery, or PTA) from index hospitalization through 6 moth follow-up
|
6 month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Thomas P. Davis, MD, St. John Hospital & Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
April 26, 2010
First Submitted That Met QC Criteria
September 17, 2010
First Posted (Estimate)
September 20, 2010
Study Record Updates
Last Update Posted (Estimate)
September 10, 2013
Last Update Submitted That Met QC Criteria
September 6, 2013
Last Verified
September 1, 2012
More Information
Terms related to this study
Other Study ID Numbers
- CR1055-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Total Occlusion of Artery of the Extremities
-
ReFlow Medical, Inc.CompletedChronic Total Occlusion of Artery of the ExtremitiesUnited States
-
University of PatrasUnknownChronic Total Occlusion of Artery of the ExtremitiesGreece, Italy, United Kingdom
-
SoundBite Medical Solutions, Inc.ethica Clinical Research Inc.; Prairie Vascular Research Inc.CompletedChronic Total Occlusion of Arteries of the ExtremitiesUnited States, Canada
-
Versono Medical LtdCompletedChronic Total Occlusion of Arteries of the ExtremitiesDominican Republic
-
SoundBite Medical Solutions, Inc.Montreal Heart Institute; ethica Clinical Research Inc.WithdrawnPeripheral Arterial Occlusive Disease | Chronic Total Occlusion of Artery of the ExtremitiesAustria, Germany
-
SoundBite Medical Solutions, Inc.RecruitingChronic Total Occlusion of Artery of the ExtremitiesUnited States, Austria, Germany
-
University Hospital UlmRecruitingChronic Total Occlusion | Chronic Total Occlusion of Coronary ArteryGermany
-
North Texas Veterans Healthcare SystemTerminatedPeripheral Vascular Diseases | Chronic Total Occlusion of Artery of the ExtremitiesUnited States
-
Shanghai MicroPort Rhythm MedTech Co., Ltd.The First Affiliated Hospital of Nanchang University; Shanghai Zhongshan Hospital and other collaboratorsRecruitingChronic Total Occlusion of Coronary ArteryChina
-
Seung-Whan Lee, M.D., Ph.D.Medtronic; Abbott Medical Devices; Biotronik SE & Co. KG; Dio MedicalRecruitingChronic Total Occlusion of Coronary ArteryKorea, Republic of
Clinical Trials on 1. CROSSER System
-
Transseptal Solutions Ltd.Meditrial Europe Ltd.CompletedAtrial FibrillationFrance, Germany
-
Yale UniversityBoston Scientific CorporationTerminatedSymptomatic Femoro-popliteal Chronic Total OcclusionUnited States
-
AVAVA, Inc.Completed
-
Piccolo MedicalCompleted
-
Abiomed Inc.SuspendedHeart Failure | Cardiopulmonary Bypass | ARDSUnited States
-
Istanbul UniversityCompletedTransversus Abdominis Plane Block
-
New York State Psychiatric InstituteActive, not recruitingPain | Abuse, DrugUnited States
-
Khon Kaen UniversityCompleted
-
Boston Scientific CorporationActive, not recruitingPersistent Atrial FibrillationUnited States, Belgium, Canada, Spain